To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

Prior treatment

• Patients with a history of severe drug hypersensitivity or hypersensitivity to the investigational drug, its components, or drugs within the same class.
• Patients with a confirmed specific medical history or a past surgical history.
• Those who have administered other investigational products or have received investigational medical device procedures within 4 weeks of the baseline

Other

• Individuals with dysphagia
• Patients with specific comorbidities or medical abnormalities.
• Pregnant women, lactating women, or women of childbearing potential who do not agree to use appropriate contraception during the clinical trial period and for 24 weeks after administration of the investigational medicinal product.
• Other patients who are inappropriate or unable to participate in this clinical study at the discretion of the investigator.

• Histologically or cytologically confirmed recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer \[High-grade serous carcinoma (HGSC), Grade 2/3 endometrioid carcinoma\]
• Patients whose BRCA 1/2 gene mutation status and/or Homologous Recombination Deficiency (HRD) status.
• Patients who received platinum-based chemotherapy followed by PARP inhibitor maintenance therapy,
• Patients who had received chemotherapy before participating in the clinical trial and responded to platinum-based chemotherapy.
• Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• Individuals with confirmed adequate hematological, renal, and hepatic function (laboratory tests may be repeated once during the screening period)